Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

EuroIntervention 2018;13:1561-1564 published online October 2017. DOI: 10.4244/EIJ-D-17-00873

Bernard Chevalier
Bernard Chevalier1*, MD; Angel Cequier2, MD; Dariusz Dudek3, MD; Michael Haude4, MD; Didier Carrie5, MD, PhD; Manel Sabaté6, MD, PhD; Stephan Windecker7, MD, PhD; Sebastian Reith8, MD; Manuel de Sousa Almeida9, MD, PhD; Gianluca Campo10, MD; Andres Iñiguez11, MD; Yoshi Onuma12, MD, PhD; Patrick W. Serruys13, MD, PhD
1. Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France; 2. Bellvitge University Hospital, Barcelona, Spain; 3. Department of Cardiology and Cardiovascular Interventions, Institute of Cardiology, Jagiellonian University, Krakow, Po

Transient scaffolding using bioresorbable drug-eluting polymeric platforms aims to improve late clinical outcomes through restoration of vasomotion, adaptive shear stress, late plaque regression and expansive remodelling. How

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Stents and scaffolds
Read next article
Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials

Latest news